Overall, it appears that SGLT2 inhibitors at least tend to decrease, rather than increase, events of SCD, but further de novo studies that take into account factors of a small event rate of SCD compared with that of heart failure or kidney disease, clear definition of SCD, and patients' backgrounds, are needed to conclude whether SGLT2 inhibitors can prevent SCD and/or VAs. This evidence concerns the gene SLC5A2 and Schnyder corneal dystrophy.